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Abstract
Experimental models of sepsis-induced pulmonary alterations are
important for the study of pathogenesis and for potential intervention
therapies. The objective of the present study was to characterize lung
dysfunction (low PaO2 and high PaCO2, and increased cellular infil-
tration, protein extravasation, and malondialdehyde (MDA) produc-
tion assessed in bronchoalveolar lavage) in a sepsis model consisting
of intraperitoneal (ip) injection of Escherichia coli and the protective
effects of pentoxifylline (PTX). Male Wistar rats (weighing between
270 and 350 g) were injected ip with 107 or 109 CFU/100 g body
weight or saline and samples were collected 2, 6, 12, and 24 h later (N
= 5 each group). PaO2, PaCO2 and pH were measured in blood, and
cellular influx, protein extravasation and MDA concentration were
measured in bronchoalveolar lavage. In a second set of experiments
either PTX or saline was administered 1 h prior to E. coli ip injection
(N = 5 each group) and the animals were observed for 6 h. Injection of
107 or 109 CFU/100 g body weight of E. coli induced acidosis,
hypoxemia, and hypercapnia. An increased (P < 0.05) cell influx was
observed in bronchoalveolar lavage, with a predominance of neutro-
phils. Total protein and MDA concentrations were also higher (P <
0.05) in the septic groups compared to control. A higher tumor
necrosis factor-alpha (P < 0.05) concentration was also found in these
animals. Changes in all parameters were more pronounced with the
higher bacterial inoculum. PTX administered prior to sepsis reduced
(P < 0.05) most functional alterations. These data show that an E. coli
ip inoculum is a good model for the induction of lung dysfunction in
sepsis, and suitable for studies of therapeutic interventions.
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Introduction
In the past two decades our knowledge of
the pathophysiology of acute lung injury and
acute respiratory distress syndrome (ARDS)
has improved substantially (1). Multiple com-
ponents of the inflammatory response have
been demonstrated to be involved in these
disorders in clinical and experimental stud-
ies (1-5).
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Sepsis is defined as the systemic inflam-
matory response syndrome caused by infec-
tion (6), characterized by a high incidence of
lethality (7,8). Lethality in sepsis is directly
associated with organ dysfunction, and ARDS
secondary to sepsis represents the ultimate
event (9). Sepsis results from the release of
diverse mediators, amongst which proinflam-
matory cytokines such as tumor necrosis fac-
tor-α (TNF-α) and interleukin-1ß (IL-1ß),
which are triggered by microorganisms or
products thereof and host-cell interactions (10).
Sepsis has been studied experimentally by
infusion of lipopolysaccharide (LPS) and dead
or live bacteria, and the cecal ligation and
puncture (CLP) procedure in order to mimic
features of the septic state in humans (11).
Animals develop progressive bacteremia, with
the release of multiple cytokines and chemo-
kines into plasma, hypermetabolism, fever/
hypothermia, and other clinical features simi-
lar to those found in humans with sepsis (11).
The main property of the lungs, gas exchange,
combined with their delicate anatomical ar-
chitecture, render them vulnerable during sep-
sis.
Various drugs blocking TNF production
by LPS-activated macrophages in vitro have
been used to reduce LPS toxicity in vivo,
among them are pentoxifylline (PTX) and its
derivative lisofylline (12). PTX is a potent
phosphodiesterase inhibitor that also affects
bacterial translocation (13). The hemorheologic
effects of PTX are due to increased red blood
cell deformability and to reduced blood vis-
cosity. However, the primary biological activ-
ity of PTX is the suppression of TNF-α pro-
duction, which occurs through adenylcyclase
activation and increased intracellular AMP
concentration (14).
We have shown that PTX protects lung
dysfunction secondary to ventilatory support
(ventilator-induced lung injury) by abolishing
the local and systemic release of TNF-α and
IL-1ß (15).
The goal of the present study was to estab-
lish a model of lung dysfunction in sepsis that
may be useful to study the mechanisms of the
disorder and to test preventive therapeutic
interventions. We expected that PTX would
modify the synthesis of proinflammatory me-
diators during sepsis-induced acute lung in-
jury and reduce the dysfunction of the organ.
Material and Methods
The experimental protocol was reviewed
and approved by the Ethics Committee of the
Federal University of São Paulo, in compli-
ance with the Guide for Care and Use of
Laboratory Animals.
Experimental design
Bacteria. The bacteria used in the experi-
ments were obtained from the mesenteric
lymph nodes and Peyer’s patch of animals
submitted to antibiotic therapy (metronida-
zole and tetracycline) for 10 days. The bacte-
ria were classified as Escherichia coli R-6 on
the basis of biochemistry and morphology.
Viable E. coli cells were suspended as 107 and/
or 109 colony forming units (CFU)/mL, and 1
mL/100 g of body weight was injected intra-
peritoneally (ip) into the rats.
Animals. Male Wistar rats (UNIFESP, São
Paulo, SP, Brazil), 270-350 g body weight,
were used in this study. Control animals re-
ceived saline infusion (G1, N = 20). Sepsis
was induced by ip injection of 107 (G2, N = 20)
and 109 CFU/100 g body weight (G3, N = 20)
of E. coli bacteria. The animals were main-
tained alive and breathing spontaneously dur-
ing 2-, 6-, 12-, and 24-h periods (N = 5 per
group per time).
The effect of PTX was evaluated in ani-
mals (N = 15) receiving 107 CFU/100 g body
weight inoculum. Animals received PTX (20
mg/kg body weight; Pentox, Farmasa, São
Paulo, SP, Brazil) or saline, injected via a tail
vein, 60 min prior to the ip E. coli inoculum or
saline (Sham). All animals were breathing
spontaneously during the 6-h period (chosen
accordingly to the results of lung dysfunction
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observed in the above experiments).
Experimental procedures
In these models, the presence of sepsis was
evaluated during the 6- and 12-h periods after
inoculation of the bacteria, and defined by
analogy to the criteria applied for humans.
Each animal was considered to be septic if it
satisfed at least two of the following criteria: a)
decreased PaO2 (≤70 mmHg), b) rectal tem-
perature above 38ºC or below 36ºC, and c)
increased respiratory rate (≥105 breaths/min).
Surgical procedures. At different times
following E. coli injection (2, 6, 12, and 24 h)
the animals were anesthetized with an ip injec-
tion of 50 mg/kg sodium thiopental (Thio-
nembutal, Abbott, Sao Paulo, SP, Brazil). Tra-
cheostomy was performed after local anesthe-
sia with 1% lidocaine and a 14-GA cannula
was inserted into the trachea. Sterile PE50
catheters were inserted into the left internal
carotid artery for blood gas sampling.
Bronchoalveolar lavage (BAL). The tho-
racic cavity was opened after anesthesia with
sodium thiopental. The lung and structures
were removed and weighed. The left lung was
tied and the right lung was washed three times
with 30 mL/kg normal saline at 4ºC. Lavage
fluids were kept separate and centrifuged at
400 g for 10 min at 4ºC and the supernatants
were frozen immediately on dry ice and stored
at -80ºC.
Laboratory parameters
Blood gases. Blood samples were obtained
from the left internal carotid artery as de-
scribed above for pH, PaO2 and PaCO2 analy-
sis (Radiometer, ABL-520, Copenhagen, Den-
mark).
Wet/dry weight ratio of the lungs. The lung
wet/dry ratio was determined by removing
and washing the right lung 2, 6, 12, and 24 h
after ip inoculum or saline injection. Lungs
were dried in an oven at 80ºC for at least 72 h.
Protein leakage. A 1-mL aliquot of BAL
was used to measure total protein by a Lowry
assay.
Cell count. Total cell concentrations in the
BAL were determined in a Bürker chamber
under a microscope at 100X magnification
immediately after specimen collection.
Differential cell counts (neutrophils and
macrophages) were performed after cytocen-
trifugation and May-Grünwald-Giemsa stain-
ing using a light  microscope at 400X magni-
fication.
Measurement of malondialdehyde (MDA).
As an index of lipid peroxidation we used the
generation of thiobarbituric acid reactive spe-
cies (TBARS) and MDA during an acid-heat-
ing reaction as previously described (15).
Briefly, the samples were mixed with 1 mL
10% trichloroacetic acid and 1 ml 0.67% thio-
barbituric acid, then heated in a boiling water
bath for 15 min. MDA was determined by
absorbance at 535 nm.
Cytokine enzyme-linked immunosorbent
assay (ELISA). TNF-α protein concentrations
in BAL were measured using a commercially
available ELISA (BD OptEIA, BD Bio-
sciences, San Diego, CA, USA) according to
manufacturer instructions. Results were ana-
lyzed by spectrophotometry at 450 nm using
an ELISA microplate reader. Threshold sensi-
tivity was 5 pg/mL.
Statistical analysis
Statistical analysis was carried out using
the SPSS statistical software (SPSS 10.0, SPSS
Science, Chicago, IL, USA). Data are reported
as means ± SD. Values were compared by
ANOVA followed by the Tukey-Kramer mul-
tiple comparisons test, with the level of signif-
icance set at P < 0.05.
Results
Pulmonary dysfunction induced by
intraperitoneally injected E. coli
Blood gas evaluations. Injection of 107
1458
Braz J Med Biol Res 39(11) 2006
I.S. Oliveira-Junior et al.
mals challenged with 109 CFU/100 g body
weight than with 107 CFU/100 g body weight
(Figure 1A and B). A trend to return to
baseline levels was observed in both groups
after 24 h, although the rats injected with 109
CFU/100 g body weight continued to have
abnormal values.
Bronchoalveolar lavage
Total and differential cell counts. Sepsis
induced an increased total cell count in BAL
fluid after 6 and 12 h in the groups inocu-
lated with 107 and 109 CFU/100 g body
weight compared to control. While total cell
counts returned to baseline levels in rats
injected with 107 CFU/100 g body weight,
they remained elevated in those injected with
109 CFU after 24 h. The percentage of neu-
trophils in BAL increased in both septic
groups 6, 12, and 24 h after the inoculum
compared to control. In contrast, a decrease
in macrophage count was observed in the
groups injected with 107 and 109 CFU/100 g
body weight after 6 and 12 h. The percentage
of macrophages remained lower in both
groups after 24 h, although trend to return to
baseline levels was observed in the 107 CFU
Figure 1. Effect of an ip Escheri-
chia coli inoculum on blood
PaO2 (A) and PaCO2 (B) in rats
treated with 107 and 109 colony
forming units (CFU)/100 g body
weight. Samples were collected
after 2, 6, 12, and 24 h from dif-
ferent groups of animals that re-
ceived ip injection of saline (con-
trol) and the E. coli inoculum.
Data are reported as means ±
SD for 5 animals in each group.
*P < 0.05 indicates a significant
difference between 107 and 109
CFU/100 g body weight and the
control group at the same time.
+P < 0.05 indicates a significant
difference between 107 and 109
CFU/100 g body weight groups
at the same time (ANOVA fol-
lowed by the Tukey-Kramer mul-
tiple comparisons test).
(G2) and 109 CFU/100 g body weight (G3)
of E. coli resulted in acidosis, hypoxemia,
and hypercapnia, observed for 6 and 12 h
following the bacterial inoculum, with more
pronounced alterations being found in ani-
Table 1. Total cell, neutrophil and macrophage counts in the bronchoalveolar lavage fluid of rats 2, 6, 12, and
24 h after intraperitoneal Escherichia coli injection.
 2 h  6 h  12 h  24 h
G1 (controls)
Total cells (x 106/mL) 2.0 ± 0.7 2.2 ± 0.8 2.2 ± 1.1 2.4 ± 1.1
Neutrophils (%) 22.8 ± 2.8 23.6 ± 2.6 23.8 ± 1.9 23.2 ± 2.2
Macrophages (%) 64.6 ± 3.8 63.8 ± 3.6 64.8 ± 1.9 65.4 ± 2.3
G2 (107 CFU/100 g body weight)
Total cells (x 106/mL) 2.2 ± 0.4 4.8 ± 0.8* 5.0 ± 1.0* 2.8 ± 0.8
Neutrophils (%) 22.0 ± 2.1 47.6 ± 4.5* 42.6 ± 1.3* 25.8 ± 1.9
Macrophages (%) 66.4 ± 3.6 28.8 ± 4.9* 34.2 ± 0.8* 59.8 ± 2.2*
G3 (109 CFU/100 g body weight)
Total cells (x 106/mL) 2.0 ± 0.7 5.2 ± 0.8* 6.0 ± 1.0* 4.8 ± 0.8*+
Neutrophils (%) 25.8 ± 2.4 43.0 ± 3.5* 43.6 ± 2.1* 36.6 ± 2.3*+
Macrophages (%) 61.0 ± 2.3 34.0 ± 3.5* 28.4 ± 2.2*+ 40.4 ± 2.1*+
Data are reported as means ± SD for 5 animals in each group. CFU = colony forming units.
*P < 0.05 compared to G1; +P < 0.05 compared to G2 (ANOVA followed by the Tukey-Kramer multiple
comparisons test).
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group (Table 1).
Wet/dry weight ratio. The changes in the
lung wet/dry weight ratio measured at the
various time points after saline or inoculum
injection are shown in Table 2. The bacterial
injections elicited a significant rise in the
wet/dry ratio after 6 h (P < 0.0001) and 12 h
(P < 0.0001) compared to control.
Protein leakage and TBARS-MDA. Total
protein concentration in lavage fluid did not
differ between groups 2 h after ip injection,
but increased in the G2 and G3 groups after
6 and 12 h. A trend to return to baseline
levels was observed in the G2 group after 24
h. TBARS-MDA concentration in BAL was
higher in the rats receiving E. coli injection
than in controls (Table 2).
Cytokine. Intraperitoneally injected bac-
teria induced TNF-α in the lung, detected in
BAL. TNF-α levels higher than control were
detected 2 h after the inoculum in rats in-
jected with 109 CFU; they increased at 6 h,
reached a peak at 12 h, and declined 24 h
after the inoculum. TNF-α levels were higher
24 h after 109 CFU/100 g body weight (73 ±
12.2 pg/mL) than after 107 CFU/100 g body
weight (35 ± 10.9 pg/mL) E. coli (Figure 2).
Protective effects of pentoxifylline
Blood gas sampling. Administration of
PTX prior to ip bacterial injection reversed
the decrease in PaO2 (65 ± 1.9 mmHg (con-
trol, C-Sepsis) compared to 91 ± 5.1 mmHg
(PTX + Sepsis)) and partially reversed the
increase in PaCO2 induced by ip injection of
E. coli (57 ± 1.6 mmHg (C-Sepsis) com-
pared to 45 ± 4.5 mmHg (PTX + Sepsis))
observed 6 h after E. coli infusion (Figure 3).
Biological determinations
Total and differential cell counts. PTX
infusion decreased cellularity and the per-
centage of neutrophils and increased the per-
centage of macrophages observed in the PTX
+ Sepsis group (Table 3).
Oxidative stress. MDA concentrations in
BAL decreased in the PTX + Sepsis group
compared to the C-Sepsis group (Table 3).
Wet/dry weight ratio. The changes in the
wet/dry weight ratio of the lung measured
Table 2. Total proteins and thiobarbituric acid reactive species-malondialdehyde (TBARS-MDA) in broncho-
alveolar lavage fluid and wet/dry (W/D) weight ratio of rats 2, 6, 12, and 24 h after intraperitoneal Escherichia
coli injection.
 2 h  6 h  12 h  24 h
Total protein (mg/mL)
G1 2.2 ± 0.8 2.8 ± 0.8 3.4 ± 1.1 3.2 ± 1.3
G2 3.2 ± 1.6 21.2 ± 0.4* 21.8 ± 0.4* 6.8 ± 1.1*
G3 5.2 ± 1.8* 26.2 ± 0.8*+ 23.4 ± 0.5*+ 22.2 ± 0.8*+
TBARS-MDA (ng/mL)
G1 112.2 ± 3.3 111.2 ± 5.2 110.2 ± 4.8 112.4 ± 5.1
G2 119.4 ± 0.9* 424.6 ± 3.4* 437.2 ± 8.6* 383.2 ± 15.1*
G3 224.4 ± 2.1*+ 469.8 ± 13.4*+ 450.2 ± 14.9* 421.4 ± 22.2*+
W/D weight ratio (g)
G1 9.0 ± 1.0 9.7 ± 5.7 10.2 ± 1.3 10.6 ± 1.4
G2 10.4 ± 0.3 13.6 ± 1.2* 13.2 ± 0.8* 11.3 ± 1.3
G3 9.4 ± 0.8 14.1 ± 1.9* 15.2 ± 1.1*+ 11.2 ± 0.5
Data are reported as means ± SD for 5 animals in each group. G1 = control; G2 = 107 CFU E. coli/100 g body
weight; G3 = 109 CFU E. coli/100 g body weight.
*P < 0.05 compared to G1; +P < 0.05 compared to G2 (ANOVA followed by the Tukey-Kramer multiple
comparisons test).
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Figure 2. Effect of an ip Escherichia coli inoculum on
tumor necrosis factor-alpha (TNF-α) in bronchoal-
veolar lavage of rats treated with 107 and 109 colony
forming units (CFU)/100 g body weight. Bronchoal-
veolar lavage was collected after 2, 6, 12, and 24 h
from different groups of animals that received an ip
injection of saline (control) or the E. coli inoculum,
and TNF levels were measured by ELISA. Data are
reported as mean ± SD for 5 animals in each group.
*P < 0.05 indicates a significant difference between
107 and 109 CFU/100 g body weight and control
group at the same time. +P < 0.05 indicates a signifi-
cant difference between 107 and 109 CFU/100 g
body weight groups at the same time (ANOVA fol-
lowed by the Tukey-Kramer multiple comparisons
test).
Figure 3. Effects of pentoxifylline (PTX) on blood gases exchanges (PaO2 and PaCO2) and on TNF-α levels in bronchoalveolar lavage in sepsis-
induced acute lung injury. Rats received PTX or saline 1 h prior to the ip injection of 107 CFU/100 g body weight. Blood samples and bronchoalveolar
lavage were collected 6 h after bacterial inoculation. TNF-α levels were measured by ELISA. Data are reported as mean ± SD for 5 animals. *P < 0.05
compared to Control-Sham;  +P < 0.05 compared to Control-Sepsis (ANOVA followed by the Tukey-Kramer multiple comparisons test).
Table 3. Total cells, neutrophils, macrophages, total proteins, and thiobarbituric acid reactive species-
malondialdehyde (TBARS-MDA) in bronchoalveolar lavage fluid, and wet/dry (W/D) weight ratio of spontane-
ous breathing rats, measured at the end of 6 h.
Control-Sham Control-Sepsis PTX + Sepsis
Total cells (x 106/mL) 2.4 ± 0.5 6.0 ± 0.7* 3.2 ± 0.4*
Neutrophils (%) 9.0 ± 2.0 58.2 ± 3.3* 12.0 ± 1.4*
Macrophages (%) 64.2 ± 2.2 12.2 ± 1.1* 60.4 ± 3.3*
Total protein (mg/mL) 4.2 ± 0.3 21.2 ± 1.3* 6.5 ± 0.7*+
TBARS-MDA (ng/mL) 117.6 ± 1.8 469.8 ± 36.8* 281.4 ± 48.4*+
W/D weight ratio (g) 7.6 ± 0.5 11.2 ± 1.1* 8.6 ± 0.5*+
Data are reported as means ± SD for 5 animals in each group. Animals received saline (Control) or 20 mg/kg
body weight pentoxifylline (PTX) 60 min prior to ip E. coli inoculum (Sepsis) or saline (Sham).
*P < 0.05 compared to control-sham; +P < 0.05 compared to control-sepsis (ANOVA followed by the Tukey-
Kramer multiple comparisons test).
1461
Braz J Med Biol Res 39(11) 2006
Lung inflammation in a sepsis-induced ALI model
after PTX or inoculum injection are shown
in Table 3.
Cytokine. TNF-α levels were significantly
increased in the C-Sepsis group (38.2 ± 3.11
pg/mL) compared to the C-Sham group (19
± 4.39 pg/mL). The levels did not decrease
significantly in the PTX + Sepsis group com-
pared to the C-Sepsis group (Figure 3).
Discussion
The present results show an extensive
pulmonary dysfunction following ip injected
E. coli. Pulmonary dysfunction complicat-
ing sepsis, indicated by ARDS, is known to
be a major factor affecting morbidity and
mortality of septic patients (16). Thus, the
development of a sepsis model with well-
defined respiratory dysfunction is important
both as a tool to understand the pathogenesis
of the disorder and as a model to test poten-
tial interventions. Different experimental
approaches have been used to study pulmo-
nary dysfunction in sepsis, among them CLP
(17) and injection of LPS (18). The CLP
model has been used very often because it
mimics human peritoneal sepsis (17). Sal-
kowski et al. (19) reported that the height of
intraperitoneal inflammation and lung dys-
function is related to the number of cecal
punctures. However, Malloy et al. (20)
showed that this procedure did not result in
severe pulmonary edema since total alveolar
protein measurements and wet/dry ratios
were similar in the sham and septic groups.
LPS toxicity has been used for models of
acute lung injury, administered both as in-
travenous injection and as tracheal instilla-
tion. Direct intravenous injection induces
elevations in catecholamine levels in the
pulmonary and systemic circulation as well
as a rapid increase in neutrophil number and
proinflammatory cytokine expression in the
lungs (21). Fan et al. (22) demonstrated that
LPS alone caused a small increase in BAL
fluid neutrophil counts, but animals sub-
jected to shock before LPS exhibited a fur-
ther three-fold increase in neutrophil num-
bers. Intratracheal administration of LPS in-
creased protein and cytokine concentrations
and inflammatory cells in BAL fluid (23).
Studies with LPS have led to important break-
throughs in our understanding of the patho-
physiology of sepsis, but they are restricted
to the use of a toxin rather than a live bacte-
rium. Despite the increasing interest in CLP,
we considered it appropriate to use ip injec-
tion in our study in order to avoid the inflam-
matory response induced by the surgical
procedure required in that model.
We described here the lung derangements
seen in rats injected ip with E. coli. Pulmo-
nary dysfunction was characterized by low
PaO2 and high PaCO2 saturation in blood,
and increased cellular infiltration, protein
extravasation, and MDA production assessed
in BAL.
Increased cellularity was observed in
BAL, with a predominance of neutrophils in
septic animals. Accordingly, an increased
MDA concentration was found in BAL from
these animals, probably resulting from in-
creased neutrophil influx, enhanced cellular
activity, and increased reactive oxygen/ni-
trogen species production. Interestingly, all
alterations observed were more profound
and long-lasting with the higher (109 CFU/
100 g body weight) than with the lower (107
CFU/100 g body weight) inoculum.
The involvement of inflammatory me-
diators in lung dysfunction was assessed by
the measurement of TNF-α, a pro-inflam-
matory cytokine, in BAL. Levels of TNF-α
were higher in septic animals than in con-
trols. TNF-α has been implicated as an im-
portant mediator in ARDS because of its
effect on endothelial cells as well as on
innate immunity cells. This cytokine has
been implicated in the activation of endothe-
lial cells with secretion of secondary media-
tors, including platelet-aggregating factor and
nitric oxide, and expression of adhesion
molecules as well as of pro-coagulant fac-
tors (24). Furthermore, it may enhance mon-
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ocyte and neutrophil activity in an autocrine/
paracrine fashion (25,26).
The potential use of this model for inter-
vention therapy was assessed by testing the
protective effect of PTX. PTX is a phospho-
diesterase inhibitor that has been shown to
decrease TNF-α levels and to down-regu-
late neutrophil activation, probably by in-
creasing intracellular cyclic AMP (27). We
have previously shown that PTX protects
rats from lung injury induced by ventilation
with a high tidal volume (15).
Since Chalkiadakis et al. (28) reported
the beneficial effects of PTX during sepsis
in 1985, several studies have demonstrated
that the administration of PTX during sepsis
or endotoxic shock preserves cardiac output
and small intestine microvascular blood flow
(29), reduces multiple organ damage (30),
prevents TNF-α-induced lung injury (31),
improves tissue oxygen extraction capabil-
ity (32) and oxygen use (33), and increases
the survival of septic animals (34). Although
the precise mechanisms responsible for the
beneficial effects of PTX in sepsis remain
unknown, studies have indicated that PTX
increases intracellular cAMP levels, which
increase the activity of protein kinase A
(cAMP-dependent kinase) and up-regulate
the cAMP-dependent response of element-
binding protein (a nuclear factor) to down-
regulate the expression of TNF-α messenger
RNA (35). In addition to the down-regula-
tion of TNF-α by PTX, Voisin et al. (36)
reported that pretreatment with this agent in
a rat model of E. coli bacteremia prevented
the increase of IL-1 and IL-6.
We found that pretreatment with PTX
could attenuate most of the sepsis-induced
functional lung alterations. Whether such
effect would be observed if PTX were ad-
ministered after the insult requires further
investigation.
We found no statistically significant dif-
ference in the BAL levels of TNF-α when
comparing C-Sepsis and PTX + Sepsis ani-
mals. This may be due to the PTX concentra-
tion used in the study. Also, an effect on
TNF-α levels at earlier time points cannot be
excluded. Alternatively, PTX could afford
protection by its effects on inflammatory
cells. Studies evaluating the effects of PTX
on adhesion molecule expression have shown
decreased P-selectin expression after hem-
orrhagic shock and decreased proinflamma-
tory cytokine-induced ICAM-1 expression
in human pulmonary epithelial cells and poly-
morphonuclear leukocytes (11,17,37).
The present study shows that an E. coli ip
inoculum provides a good model for the
induction of lung dysfunction in sepsis, suit-
able for studies of therapeutic interventions.
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